Gastrografin in Postoperative Ileus
- Registration Number
- NCT01648972
- Lead Sponsor
- University of Auckland, New Zealand
- Brief Summary
After abdominal surgery there is a period of unavoidable dysfunction of the gut. During this time patients are often unable to eat and drink, and do not pass any flatus or stool. Though this resolves within a few days for most, there are a significant number (around 30%) who go on to have a prolonged period of this dysfunction known clinically as postoperative ileus. It has been clearly shown that this group of patients have worse health outcomes and spend a longer time in hospital.
The aim of this study is to trial a drug - gastrografin - in the management of prolonged postoperative ileus. Gastrografin is safe, economical, readily available, and has been used with great success in the similar condition of bowel obstruction. It is predicted that gastrografin will shorten the duration of a prolonged postoperative ileus, thus affording affected patients a better outcome from surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
- Age > 18 years.
- Current inpatient following elective laparoscopic or open surgery.
- Classified as having prolonged postoperative ileus.
- Able to understand risks/benefits of the study.
- Able to give informed consent.
- Pregnancy.
- ASA of 4 or greater.
- Previous allergic reaction to gastrografin or iodinated contrast agents.
- Manifest hyperthyroidism.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Gastrografin Gastrografin - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Time from diagnosis (and administration of study drug) to resolution of prolonged postoperative ileus.
- Secondary Outcome Measures
Name Time Method Length of hospital stay (days) Days
Trial Locations
- Locations (1)
Auckland City Hospital
🇳🇿Auckland, AKL, New Zealand